百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目

智通财经
Jan 12

智通财经APP讯,百奥赛图-B(02315)发布公告,近日,公司与育世博股份有限公司(育世博)达成一项选择权与许可协议,旨在通过结构化的评估机制,对双特异性抗体药物偶联物(BsADC)项目开展系统性评估,从而进一步加速双特异性抗体双药物偶联物(BsAD2C)的开发进程。

该协议将授予育世博一项选择权以获得百奥赛图两项BsADC项目的全球独家许可。根据该协议条款,百奥赛图将有权获得选择权首付款;在育世博行使相关选择权后,百奥赛图还可获得包括选择权行使费、开发和监管里程碑付款、商业化里程碑付款以及未来产品销售分成在内的后续款项。

该协议是公司在年初与育世博开展的联合开发合作基础上进一步深化的合作。此前,双方的合作重点聚焦于对有成药潜力的双特异性抗体及双载荷抗体药物偶联物(ADC)候选项目的评估与筛选。基于已完成的临床前研究成果,公司认为,将百奥赛图的RenLite®全人共轻链抗体开发平台与育世博的抗体-双药物偶联(AD2C)技术相结合,为新一代BsAD2C的开发提供了极具前景的技术路径。

双方此次拓展合作旨在充分发挥各自平台的互补优势,推进新一代ADC分子设计,以期在一定程度上克服传统ADC项目中所观察到的若干局限性。合作团队正稳步推进候选项目的关键评估节点,相关推进决策将基于持续获得的研究数据,并结合育世博内部流程及选择权行权标准综合作出。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10